Ensuring the Future Health of Healthcare

Contact Us Or, call us for a free consultation (800) 380-6496

Who We Are

Octavius Health is a Healthcare Investment & Management Company who actively drives enhanced results to Healthcare Organizations across North America. Our ultimate goal is to improve the quality of Healthcare through platforms and programs that have been specifically developed for the 3 main parties in Healthcare - the Insurer, The Provider, and the Patient.

Learn More

What We Do

• Laboratory Management
• Pharmacy Fulfillment & Compliance Management
• Pharmacy Benefit Management

Learn More

Who We Work With

• Patients
• Providers
• Insurance Companies
• Employers

Learn More

Why We Do It

Because the right way should be the only way.

Experienced Professionals With Industry Knowledge

We are ready to help your organization with a diverse array of medical industry concerns. In addition to marketplace intelligence, we also offer innovative revenue-driving programs, general due diligence, and community outreach programs. Our accomplished team of professionals will provide you with a satisfying and comprehensive experience.

Everything You Need Under One Roof.

Synergy is key. Whatever your goals are our team members have the necessary industry knowledge to help you achieve your true growth potential. Our dynamic platforms are applicable to all constituents of the healthcare continuum.

Comprehensive Compliance and Legal Coverage.

When you have Octavius Health behind you, you have a power-house of adept professionals serving as your intermediary. We ensure that your entity is protected and remains compliant with all rules and regulations, no matter what stage of growth you are at. This allows you and your staff to focus on day-to-day internal processes.

Industry News

U.S Govenment Announces $450M Deal With Regeneron Pharmaceuticals

The combined forces of the Biomedical Advanced Research and Development Authority (BARDA), the U.S. Department of Health and Human Services, and the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense have just approved a $450M deal with Regeneron Pharmaceuticals, Inc. This $450 million contract is for Regeneron to manufacture and supply REGN-COV2. REGN-COV2 is Regeneron's investigational double-antibody cocktail for COVID-19 treatment and prevention. Regeneron is currently in Phase 2/3 of clinical trials for the treatment of COVID-19 and in a Phase 3 trial for the prevention of COVID-19. If clinical trials are successful, the FDA may grant Emergency Use Authorization (EUA) so this can immediately be manufactured for the US. The agreement "covers a...


Patients Demand Pharma Pricing Transparency

Patients want transparency.  In recent years, patients are facing higher...


Lawmakers Urge HHS To Increase Clinical Lab Funding

Due to the extensive work that clinical laboratories have been...


CA and NY Voting on Additional COVID 19 Lab Funding

In recent news, Tom Reed (NY-23) and Scott Peters (CA-52)...


US Congress Wants COVID-19 Funds To Go Directly to Labs

There are efforts being made by 30 US Congress members...


Our Values